Compare WYETH LTD with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs LUPIN - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD LUPIN WYETH LTD/
LUPIN
 
P/E (TTM) x 27.7 47.5 58.4% View Chart
P/BV x 5.3 2.4 219.9% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   LUPIN
EQUITY SHARE DATA
    WYETH LTD
Mar-13
LUPIN
Mar-19
WYETH LTD/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,044986 105.9%   
Low Rs818720 113.5%   
Sales per share (Unadj.) Rs298.6369.5 80.8%  
Earnings per share (Unadj.) Rs57.213.4 427.0%  
Cash flow per share (Unadj.) Rs58.437.4 156.2%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.5303.7 82.1%  
Shares outstanding (eoy) m22.72452.49 5.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.12.3 135.1%   
Avg P/E ratio x16.363.6 25.6%  
P/CF ratio (eoy) x15.922.8 69.9%  
Price / Book Value ratio x3.72.8 132.9%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,157386,064 5.5%   
No. of employees `0000.517.7 2.8%   
Total wages/salary Rs m40031,513 1.3%   
Avg. sales/employee Rs Th13,787.49,453.8 145.8%   
Avg. wages/employee Rs Th813.01,782.0 45.6%   
Avg. net profit/employee Rs Th2,643.3343.0 770.7%   
INCOME DATA
Net Sales Rs m6,783167,182 4.1%  
Other income Rs m3533,640 9.7%   
Total revenues Rs m7,136170,822 4.2%   
Gross profit Rs m1,61728,822 5.6%  
Depreciation Rs m2710,850 0.2%   
Interest Rs m63,078 0.2%   
Profit before tax Rs m1,93818,534 10.5%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-5-3,400 0.2%   
Tax Rs m6329,017 7.0%   
Profit after tax Rs m1,3016,066 21.4%  
Gross profit margin %23.817.2 138.3%  
Effective tax rate %32.648.7 67.1%   
Net profit margin %19.23.6 528.4%  
BALANCE SHEET DATA
Current assets Rs m6,984138,536 5.0%   
Current liabilities Rs m2,05661,299 3.4%   
Net working cap to sales %72.646.2 157.2%  
Current ratio x3.42.3 150.3%  
Inventory Days Days9984 118.5%  
Debtors Days Days24112 21.3%  
Net fixed assets Rs m244127,516 0.2%   
Share capital Rs m227905 25.1%   
"Free" reserves Rs m5,441136,517 4.0%   
Net worth Rs m5,668137,422 4.1%   
Long term debt Rs m2566,417 0.0%   
Total assets Rs m7,901279,494 2.8%  
Interest coverage x353.37.0 5,032.5%   
Debt to equity ratio x00.5 0.9%  
Sales to assets ratio x0.90.6 143.5%   
Return on assets %16.53.3 505.3%  
Return on equity %22.94.4 519.8%  
Return on capital %34.08.9 382.1%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1559,414 0.0%   
Fx outflow Rs m2,67722,282 12.0%   
Net fx Rs m-2,66237,132 -7.2%   
CASH FLOW
From Operations Rs m92316,660 5.5%  
From Investments Rs m317-32,825 -1.0%  
From Financial Activity Rs m-4817,441 -6.5%  
Net Cashflow Rs m759-8,724 -8.7%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 51.1 0.2 25,550.0%  
Indian inst/Mut Fund % 11.3 11.3 100.0%  
FIIs % 7.2 31.9 22.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.1 301.0%  
Shareholders   21,978 98,259 22.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - SHASUN PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS